DelveInsight’s Phenylketonuria market report provides thorough comprehension of Phenylketonuria, historical and forecasted epidemiology, and Phenylketonuria market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan).
Some of the Key Highlights from the Phenylketonuria Market Report
According to DelveInsight’s Phenylketonuria epidemiology insights, the total diagnosed prevalent cases was found to be 49,887 in the 7MM in 2020.
Among the EU5 countries, Germany has the highest number of Phenylketonuria cases while Spain has the least number of cases in 2020.
According to the National PKU Alliance, there are currently more than 16,000 people in the United States who have PKU.
Key companies across the globe such as Synlogic, Censa Pharmaceuticals, Homology Medicines, Biomarin Pharmaceuticals, and others are diligently working toward the development of novel treatment therapies and devices for Phenylketonuria treatment.
Synlogic’s SYNB-618 was granted orphan drug designation by the US FDA in 2017 for the Phenylketonuria treatment, and it was also granted Fast track designation by the US FDA in 2018.
Homology Medicines is developing HMI-102, a gene therapy, for the treatment of adult patients with PKU.
Have queries? Request for the sample to get the answers for all your queries @ Phenylketonuria Treatment Options
The Phenylketonuria (PKU) market report also covers current treatment practices, emerging drugs, Phenylketonuria (PKU) market share of individual therapies, and current and forecasted Phenylketonuria (PKU) market Size from 2018 to 2030, segmented by seven major markets.
Phenylketonuria: Overview
Phenylketonuria (PKU) is an inborn metabolic error that can be detected during the first days of life through routine newborn screening. PKU is defined by the absence or deficiency of an enzyme called phenylalanine hydroxylase (PAH), which is responsible for the amino acid phenylalanine processing.
Phenylketonuria Epidemiology Segmentation
The Phenylketonuria report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
Phenylketonuria Diagnosed Prevalent Cases
Phenylketonuria Age-Specific Diagnosed Prevalent Cases
Phenylketonuria Severity-Specific Diagnosed Prevalent Cases
Phenylketonuria Diagnosed Prevalent Cases by Mutation Type
Phenylketonuria Treatment Landscape
There is currently no cure for Phenylketonuria (PKU); however, the most common treatment is a dietary restriction of phenylalanine (Phe) to the minimum required for normal growth, supplemented with specially designed medical foods. As a result, dietary therapy is the first line of Phenylketonuria treatment. Apart from this, there are some FDA-approved drugs such as Kuvan (sapropterin dihydrochloride) and Palynziq (pegvaliase-pqpz) that are used for Phenylketonuria treatment.
Phenylketonuria Market
The launch of therapies such as SYNB1618, CNSA-001, HMI-102, and others by key pharmaceutical companies such as Synlogic, Censa Pharmaceuticals, Homology Medicines, and several others are anticipated to provide a major push to the growth of the Phenylketonuria market size in the forecast period 2021-30 in the 7MM.
Get a detailed analysis of the phenylketonuria therapeutics market @ Phenylketonuria Treatment Market
Phenylketonuria Pipeline Therapies and Key Companies
SYNB1618: Synlogic
CNSA-001: Censa Pharmaceuticals
HMI-102: Homology Medicines
BMN 307: Biomarin Pharmaceuticals
Table of Contents
1.
Key insights
2.
Executive Summary of Phenylketonuria
3.
Phenylketonuria: Market Overview at a Glance
4.
Disease Background and Overview: Phenylketonuria
5.
Phenylketonuria Patient Journey
6.
Case Reports
7.
PhenylketonuriaEpidemiology and Patient Population
8.
Phenylketonuria: Country-Wise Epidemiology
9.
Phenylketonuria Treatment & Medical Practices
10.
Phenylketonuria Marketed Products
11.
Phenylketonuria Emerging Therapies
12.
Phenylketonuria Pipeline Profiles
13.
Phenylketonuria: Market Size
14.
7MM Phenylketonuria: Country-Wise Market Analysis
15.
Phenylketonuria Market Drivers
16.
Phenylketonuria Market Barriers
17.
SWOT Analysis
18.
KOL Views
19.
Phenylketonuria Reimbursement and market access
20.
Appendix
21.
DelveInsight Capabilities
22.
Disclaimer
23.
About DelveInsight
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts
Related Reports
Hyperphosphatemia Market
Get comprehensive historical and forecast analysis of Hyperphosphatemia Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Akebia Therapeutics, Vifor Fresenius Medical Care Renal Pharma, Astellas Pharma, Ardelyx, Shield Therapeutics, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/